A Checklist of key issues a branded drug patent owner's counsel should consider before filing a patent infringement suit against a generic drug manufacturer under the Hatch-Waxman Act. These issues include the activities that counsel should perform before an Abbreviated New Drug Application (ANDA) filing, the considerations in the 45-day period after receiving a Paragraph IV Notice Letter, and other factors that may impact the decision to litigate.